NCT04809623 - Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

October 18, 2022

Study Completion Date

October 18, 2022

Conditions

Cutaneous Lupus Erythematosus

Interventions

DRUG

Edecesertib

Tablets administered orally

DRUG

Placebo

Placebo to match edecesertib tablets administered orally

DRUG

Standard of Care

Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)

Trial Locations (5)

28210

DJL Clinical Research, PLLC, Charlotte

33765

Clinical Research of West Florida, Inc., Clearwater

46250

Dawes Fretzin Clincial Research Group, LLC, Indianapolis

75231

Metroplex Clinical Research Center, Dallas

90211

Wallace Rheumatic Studies Center, LLC, Beverly Hills